References
- Green JA, Dawson AA, Fell LF. Measurements of drug dosage intensity in MVPP therapy in Hodgkin’s disease. Br J Clin Pharmacol 1980; 9: 511–514.
- Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10–15.
- Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162–1170.
- Link MP, Goorin MA, Miser AW et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremities. N Engl J Med 1986; 314: 1600–1606.
- Rosen G. Preoperative chemotherapy (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten years experience. Orthopaedics 1985; 8: 659–664.
- Winkler K, Beron G, Delling G et al. Neoadjuvant chemotherapy of osteosarcoma. Results of randomized cooperative trials (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329–337.
- Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthoped 1980; 153: 106–120.
- Picci P, Bacci G, Campanacci M et al. Histological evaluation of necrosis in osteosarcoma induced by chemotherapy. Cancer 1985; 56: 1515–1521.
- Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281–1288.
- Skipper HE. On design of combination chemotherapy regimens to be used alone or in an adjuvant setting. In CI Jacquillat C, Weil M, Khayat D ed. Neoadjuvant Chemotherapy. Colloque Inserm/John Libbery Eurotext Ltd 1988; 169: 491–498.
- Redmond C, Fisher B, Wieand HS. Commentary: The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treat Rep 1983; 67: 519–526.